New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the psoriasis medication Apremilast in Canada

We at Tiefenbacher Pharmaceuticals strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada. With the same safety and efficacy profile as the brand-name product, Apremilast is approved by the U.S Food and Drug Administration (FDA) and available at a lower cost.
Apremilast is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers. We are standing out in launching the only generic version of Apremilast in the form of a starter kit (10 mg, 20 mg, and 30 mg) additionally to bottles of 30 mg tablets. This allows the product to be taken gradually to the recommended dosage, facilitating the work of physicians and pharmacists and improving the patient experience. The product has been developed and produced in TIEFENBACHER GROUP´s own state-of-the-art facilities in India and is marketed by our partner, a well-established Canadian pharmaceutical company. With this early market entry Tiefenbacher Pharmaceuticals achieves significant savings for the international health care systems and enables patients in Canada a better affordable access to a life-improving treatment. We will keep you updated about launches of this and other prodcuts in further international markets.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).  

For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on:www.tiefenbacher-pharmaceuticals.com

Tiefenbacher launch Apremilast (Psoriasis)
About Tiefenbacher Group – Pioneering Healthcare since 1963

Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.

For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email at info@tiefenbacher.com or visit us on:  www.tiefenbachergroup.com